Curis, Inc. CRIS
Curis, Inc. (Nasdaq: CRIS) is an oncology drug developer. Its lead program, emavusertib (CA-4948), is in Phase 2 for R/R primary CNS lymphoma; CLL. Its next catalyst on record is emavusertib (CA-4948): First CLL Phase 2 patient expected late Q4 2025 or early Q1 2026, with data expected at ASH in December 2026. (December 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: emavusertib (CA-4948) — First CLL Phase 2 patient expected late Q4 2025 or early Q1 2026, with data expected at ASH in December 2026. (December 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| emavusertib | PCNSL (TakeAim Lymphoma Phase 1/2 with ibrutinib) | small molecule | Phase 2 |
| emavusertib | CLL (TakeAim CLL Phase 2) | small molecule | Phase 2 |
Recent results and decisions
- Oct 16, 2026n/a Curis entered into a Securities Purchase Agreement to sell 16,666,680 shares of common stock (or pre-funded warrants) and common warrants at an effective combined price of $0.51 per share.
On October 16, 2026, Curis, Inc. entered into a Securities Purchase Agreement with the purchasers named therein for the purchase and sale of 16,666,680 shares of the Company's common stock, par value $0.01 per share (or pre-funded warrants to purchase shares of Common Stock in lieu thereof) and comm
Filing - Mar 19, 2026positive SNO poster (24 pts): 100% ORR (5/5) in BTKi-naive and 37% ORR (7/19) in BTKi-experienced patients.
5 of 5 BTKi-naïve patients achieved objective response (100% ORR)
Filing - Mar 19, 2026started Curis initiated open-label Phase 2 study of emavusertib with zanubrutinib in CLL.
Curis initiated an open label Phase 2 clinical study of emavusertib in combination with zanubrutinib, a BTKi, in patients with Chronic Lymphocytic Leukemia (CLL).
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.